Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708369 · ClinicalTrials.gov registry record · Phase 1
Alcohol Inhibits Drug Metabolism by Carboxylesterases
A Phase 1 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01708369 is a Phase 1 study that has completed, run by University of Tennessee. The registered enrollment target is 19 participants.
The verdict
NCT01708369, a Phase 1 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if alcohol is able the affect the body's ability to eliminate two commonly used medication, oseltamivir and aspirin. We hypothesize that drinking alcohol may reduce the body's ability to break down these two medications along with many others.This could affect the amount of drug in the blood which could impact how well these drugs work and whether patients have side effects.
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG Ethanol
- DRUG Oseltamivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01708369
The ClinicalTrials.gov registry entry for NCT01708369 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01708369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01708369 about?
NCT01708369 is a clinical study titled "Alcohol Inhibits Drug Metabolism by Carboxylesterases". The purpose of this study is to determine if alcohol is able the affect the body's ability to eliminate two commonly used medication, oseltamivir and aspirin. We hypothesize that drinking alcohol may reduce the body's ability to break down these two medications along with many others.This could affe...
What is the current status of trial NCT01708369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01708369?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), Ethanol (DRUG), Oseltamivir (DRUG).
Who is sponsoring clinical trial NCT01708369?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.